The advantages of using a centralized unblinded application such as an IXR are just as applicable to a small trial as to a large one. Real-time subject and supplies information to support management decisions, centralized unbiased randomization with easy stratification methods, automated supply chain management and much more. Pricing methods, however, which rely on deliverables unrelated to trial size (development milestones, validation exercises, etc) can push the cost to the trial too high.
At HMD clinical we match the cost of the IXR to the trial size and budget without offering an 'IXR Lite' or compromising on quality. Our pricing model seeks to ensure that the technology saves time and money - as technology always should - by significantly reducing the often hidden internal management costs of running the trial manually. The reduction in site errors, subject attrition, IMP wastage or mis-shipping, status report collation and CRA on-site time ensures that the ROI is positive.
